Dynavax Technologies Corporation stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Dynavax Technologies Corporation stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Dynavax Technologies Corporation do? Business model and key facts
Get the full picture of Dynavax Technologies Corporation: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees (FY): 405
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.
Stocks related to Dynavax Technologies Corporation
Selected based on industry alignment and relative market positioning.
Events and news impacting Dynavax Technologies Corporation stock
Earnings, coporate decisions and industry developments that can affect the share price.
Dynavax Technologies Corporation fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
